Biopharma deal-making loses momentum amid current uncertainties

Following a sharp drop in Q1, the purchase of patent-rich life sciences businesses may dry up this quarter as the covid-19 pandemic makes it more difficult to evaluate assets

Get unlimited access to all IAM content